GoodRx said it is expanding access to oral Ozempic (oral semaglutide) for self-pay type 2 diabetes patients through its prescription savings platform. The company described nationwide pricing of as low as $149 per month at participating pharmacies, with three dosage tiers listed: $149 for 1.5 mg, $199 for 4 mg, and $299 for 9 mg. The rollout offers a non-injectable option as Novo Nordisk expands its semaglutide portfolio, and frames the initiative around transparent shelf pricing rather than insurer-specific rates. GoodRx said the collaboration extends across Novo’s semaglutide offerings. For the broader market, the move adds competitive pressure to affordability strategies as more oral GLP-1 options emerge and payer restrictions remain a key access bottleneck. GoodRx also emphasized its consumer reach and history of cost savings, positioning the semaglutide access program as part of a direct-to-pharmacy transparency model.